As NICE and EU Joint Clinical Assessment (JCA) requirements increasingly need to be considered in parallel, manufacturers face growing pressure to generate evidence that supports multiple HTA pathways without creating unnecessary duplication, delays or access risks.
In this on-demand webinar, Remap’s HTA and market access experts, including former NICE team members, explore how organisations can align evidence strategies from the earliest stages of development to support both NICE and JCA requirements. Through practical discussion and case study analysis, the session examines where evidence expectations converge, where tailored approaches remain essential, and how early planning can improve launch readiness.
Access the Recording
What the session covers
- How NICE and JCA assessment processes compare, including where timelines, evidence requirements and decision-making align or diverge.
- Practical approaches to designing evidence strategies that support both NICE and JCA while reducing duplication and unnecessary evidence generation.
- Case study and analogue analysis demonstrating how different evidence packages perform across HTA pathways.
- Strategic considerations for organisational readiness, evidence planning and launch sequencing in an evolving European HTA landscape.
- Practical recommendations for manufacturers preparing assets for both national and EU-level assessment.